These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 9875373)
21. Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB/c mice. Kuo YC; Lee YC; Leu YL; Tsai WJ; Chang SC Antiviral Res; 2008 Nov; 80(2):206-12. PubMed ID: 18621082 [TBL] [Abstract][Full Text] [Related]
22. Intravenous foscarnet in the management of acyclovir-resistant herpes simplex virus type 2 in acute retinal necrosis in children. Khurana RN; Charonis A; Samuel MA; Gupta A; Tawansy KA Med Sci Monit; 2005 Dec; 11(12):CS75-8. PubMed ID: 16319793 [TBL] [Abstract][Full Text] [Related]
23. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375 [TBL] [Abstract][Full Text] [Related]
24. Topical treatment of cutaneous herpes simplex virus-1 infection in mice with a specially formulated caffeine gel (Cafon). Yamamura J; Koyasu M; Sato H; Kurokawa M; Yoshida Y; Amahabu Y; Shiraki K J Dermatol Sci; 1996 Apr; 12(1):50-5. PubMed ID: 8740461 [TBL] [Abstract][Full Text] [Related]
25. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. Simmons A; Nash AA J Virol; 1984 Dec; 52(3):816-21. PubMed ID: 6092713 [TBL] [Abstract][Full Text] [Related]
30. Acute morphine administration reduces white blood cells' capability to induce innate resistance against HSV-1 infection in BALB/c mice. Jamali A; Bamdad T; Soleimanjahi H; Pakdel FG; Arefian E Neuroimmunomodulation; 2007; 14(1):16-23. PubMed ID: 17700036 [TBL] [Abstract][Full Text] [Related]
31. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice. Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644 [TBL] [Abstract][Full Text] [Related]
32. Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient. Arnulf B; Chebbi F; Lefrere F; Ait Arkoub Z; Varet B; Fillet AM Bone Marrow Transplant; 2001 Oct; 28(8):799-801. PubMed ID: 11781635 [TBL] [Abstract][Full Text] [Related]
33. Treatment of Herpes simplex virus infections with topical antiviral agents. Hamuy R; Berman B Eur J Dermatol; 1998; 8(5):310-9. PubMed ID: 9683881 [TBL] [Abstract][Full Text] [Related]
34. Value of the dorsal cutaneous guinea pig model in selecting topical antiviral formulations for the treatment of recurrent herpes simplex type 1 disease. Poli G; Dall'Ara P; Binda S; Santus G; Poli A; Cocilovo A; Ponti W Arzneimittelforschung; 2001; 51(5):433-8. PubMed ID: 11413746 [TBL] [Abstract][Full Text] [Related]
35. Thymine arabinoside (Ara-T) topical and iontophoretic application for herpes simplex virus type 1 and type 2 skin infections in hairless mice. Hill JM; Wiggins CA; Kwon BS; Gentry GA; Gangarosa LP Methods Find Exp Clin Pharmacol; 1984 Jan; 6(1):17-20. PubMed ID: 6717166 [TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Hostetler KY; Rybak RJ; Beadle JR; Gardner MF; Aldern KA; Wright KN; Kern ER Antivir Chem Chemother; 2001 Jan; 12(1):61-70. PubMed ID: 11437323 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Watkins AM; Dunford PJ; Moffatt AM; Wong-Kai-In P; Holland MJ; Pole DS; Thomas GM; Martin J; Roberts NA; Mulqueen MJ Antivir Chem Chemother; 1998 Jan; 9(1):9-18. PubMed ID: 9875372 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. Schmit I; Boivin G J Infect Dis; 1999 Aug; 180(2):487-90. PubMed ID: 10395866 [TBL] [Abstract][Full Text] [Related]
39. Recent approval of Xerese in Canada: 5% acyclovir and 1% hydrocortisone topical cream in the treatment of herpes labialis. Nguyen HP; Stiegel KR; Downing C; Stiegel KR Skin Therapy Lett; 2014; 19(3):5-8. PubMed ID: 25188362 [TBL] [Abstract][Full Text] [Related]
40. Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. Iino T; Gondo H; Ohno Y; Minagawa H; Iwasaki H; Maruyama T; Nakashima H; Niho Y Bone Marrow Transplant; 1996 Dec; 18(6):1185-8. PubMed ID: 8971394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]